Naga P. Chalasani MD, FACG, FAASLD

Dr. Chalasani is considered an authority in the fields of nonalcoholic fatty liver disease (NAFLD) and drug induced liver injury (DILI), two highly significant public health problems. In a series of translational studies, he has characterized the role of leptin, adiponectin, cytochrome P450 2E1, GPI-PLD and FADS1 in human nonalcoholic steatohepatitis (NASH). Dr. Chalasani was the first to observe that individuals with NAFLD are at higher risk for cardiovascular disease and it is now evident that cardiovascular disease is the single most common cause of death in patients with NAFLD.